907 related articles for article (PubMed ID: 23474436)
1. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
2. Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
Kristal AR; Till C; Tangen CM; Goodman PJ; Neuhouser ML; Stanczyk FZ; Chu LW; Patel SK; Thompson IM; Reichardt JK; Hoque A; Platz EA; Figg WD; Van Bokhoven A; Lippman SM; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1823-32. PubMed ID: 22879203
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone suppressibility and adrenal and ovarian venous effluents of 5α-reduced C19 conjugates in hyperandrogenic women.
Stanczyk FZ; Saxena T; Lobo RA
J Steroid Biochem Mol Biol; 2014 Jan; 139():73-7. PubMed ID: 24121067
[TBL] [Abstract][Full Text] [Related]
4. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
6. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
7. Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Traish AM; Morgentaler A
J Steroid Biochem Mol Biol; 2013 Nov; 138():462. PubMed ID: 23851167
[No Abstract] [Full Text] [Related]
8. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
9. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
Labrie F; Bélanger A; Cusan L; Candas B
J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
[TBL] [Abstract][Full Text] [Related]
10. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
11. Androgen glucuronides analysis by liquid chromatography tandem-mass spectrometry: could it raise new perspectives in the diagnostic field of hormone-dependent malignancies?
Kalogera E; Pistos C; Provatopoulou X; Athanaselis S; Spiliopoulou C; Gounaris A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():24-34. PubMed ID: 24140653
[TBL] [Abstract][Full Text] [Related]
12. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
Rittmaster RS; Stoner E; Thompson DL; Nance D; Lasseter KC
J Androl; 1989; 10(4):259-62. PubMed ID: 2550402
[TBL] [Abstract][Full Text] [Related]
13. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
14. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
[TBL] [Abstract][Full Text] [Related]
16. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer.
Bélanger A; Brochu M; Cliche J
J Clin Endocrinol Metab; 1986 May; 62(5):812-5. PubMed ID: 2937801
[TBL] [Abstract][Full Text] [Related]
17. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging.
Labrie F; Bélanger A; Cusan L; Gomez JL; Candas B
J Clin Endocrinol Metab; 1997 Aug; 82(8):2396-402. PubMed ID: 9253307
[TBL] [Abstract][Full Text] [Related]
18. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
Cote RJ; Skinner EC; Salem CE; Mertes SJ; Stanczyk FZ; Henderson BE; Pike MC; Ross RK
Br J Cancer; 1998 Aug; 78(3):413-8. PubMed ID: 9703292
[TBL] [Abstract][Full Text] [Related]
19. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol.
Reddy DS
Neuroscience; 2004; 129(1):195-207. PubMed ID: 15489042
[TBL] [Abstract][Full Text] [Related]
20. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
